Curriculum Vitaes
Profile Information
- Affiliation
- Department of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine
- Degree
- 博士(医学)(名古屋大学)
- ORCID ID
https://orcid.org/0009-0005-2667-7057- J-GLOBAL ID
- 202001000562143382
- researchmap Member ID
- R000010558
Research Areas
4Research History
7-
Apr, 2024 - Present
-
Apr, 2023 - Present
-
Apr, 2023 - Present
-
Oct, 2020 - Mar, 2023
-
Jan, 2018 - Mar, 2023
Awards
2-
Mar, 2011
Papers
26-
Biological and Pharmaceutical Bulletin, 2026 Peer-reviewed<jats:title>Abstract</jats:title><jats:p>Teicoplanin is an important antimicrobial agent for methicillin-resistant<jats:italic>Staphylococcus aureus</jats:italic>infections. To enhance its clinical effectiveness while preventing adverse effects, therapeutic drug monitoring (TDM) of teicoplanin trough concentration is recommended. Given the importance of the early achievement of therapeutic concentrations for treatment success, initial dosing regimens are deliberately designed based on patient information.</jats:p><jats:p>Considerable effort has been dedicated to developing an optimal initial dose plan for specific populations; however, comprehensive strategies for tailoring teicoplanin dosing have not been successfully implemented. The initial dose planning of teicoplanin is conducted at the clinician’s discretion and is thus strongly dependent on the clinician’s experience and expertise.</jats:p><jats:p>The present study aimed to use a machine learning (ML) approach to integrate clinicians’ knowledge into a predictive model for initial teicoplanin dose planning. We first confirmed that dose planning by pharmacists dedicated to TDM (hereafter TDM pharmacists) significantly improved early therapeutic target attainment for patients without an intensive care unit or high care unit stay, providing the first evidence that dose planning of teicoplanin by experienced clinicians enhances early teicoplanin therapeutic exposure. Next, we used a dataset of teicoplanin initial dose planning by TDM pharmacists to train and implement the model, yielding a model that emulated TDM pharmacists’ decision-making for dosing. We further applied ML to cases without TDM pharmacist dose planning and found that the target attainment rate of the initial teicoplanin concentration markedly increased. Our study opens a new avenue for tailoring the initial dosing regimens of teicoplanin using a TDM pharmacist-trained ML system.</jats:p><jats:sec><jats:title>Importance</jats:title><jats:p>Teicoplanin is used for treating methicillin-resistant<jats:italic>Staphylococcus aureus</jats:italic>infections. Given the importance of early adequate teicoplanin exposure, initial dosing regimens are adjusted for patient characteristics. However, tailoring teicoplanin dosing is challenging for most clinicians. In this study, we first showed that initial dosing regimens by pharmacists dedicated to therapeutic drug monitoring significantly improved early achievement of targeted concentration. In addition, we leveraged machine learning approach to develop the predictive model that tailors initial dosing regimens at the levels of experienced pharmacists. The target attainment rate of patients without experienced pharmacists’ dose planning was significantly increased by applying the model. Therefore, machine learning approach may provide new avenues for tailoring initial teicoplanin dosing.</jats:p></jats:sec>
-
Scientific Reports, 15(1) 41783, Nov 25, 2025 Peer-reviewed
-
Neurobiology of Disease, 217 107151-107151, Oct 22, 2025 Peer-reviewed
-
Annals of Clinical and Translational Neurology, 12 2410-2421, Sep 1, 2025 Peer-reviewedABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the copy numbers of two regions of the mtDNA circular molecule (mt64‐ND1 and mt96‐ND5), were quantified in 44 PD patients and 43 controls using multiplex digital PCR. The mt96‐ND5/mt64‐ND1 ratio was calculated to estimate mtDNA deletion burden. Associations with clinical features, body composition, serum nutritional markers, and plasma energy metabolism‐related organic acids were examined. Generalized linear models (GLMs) were performed to adjust for confounders. Results CSF mt64‐ND1 and mt96‐ND5 levels were lower in PD patients than controls ( p = 0.002, p = 0.001), while the mt96‐ND5/mt64‐ND1 ratio showed no group difference. GLM analysis identified body composition indices and serum albumin as key determinants of cf‐mtDNA levels. Subgroup analysis showed lower cf‐mtDNA levels in PD patients with preserved body composition and nutritional status. The mt96‐ND5/mt64‐ND1 ratio displayed a biphasic association with body composition and an inverse correlation with plasma 2‐ketoglutaric acid, suggesting a link to energy metabolism. Interpretation CSF cf‐mtDNA levels are reduced in PD and influenced by body composition and nutritional status, supporting their role as a metabolic biomarker. While the cf‐mtDNA deletion ratio remained unchanged, its association with body composition suggests a complex interplay between mitochondrial integrity and metabolism. These findings highlight the relevance of cf‐mtDNA in PD pathophysiology and the need for further study.
-
In Vivo, 39(5) 2872-2882, Aug 28, 2025 Peer-reviewed
Misc.
61-
日本薬学会年会要旨集(Web), 145th, 2025
-
パーキンソン病・運動障害疾患コングレスプログラム・抄録集, 19th 72-72, 2025
-
日本薬学会年会要旨集(Web), 145th, 2025
-
Clinical Nutrition ESPEN, 63 1235-1236, Oct, 2024 Peer-reviewed
-
日本病院薬剤師会東海ブロック・日本薬学会東海支部合同学術大会講演要旨集, 2022 (Web), 2022
-
日本コンピュータ外科学会誌, 23(4) 326,21(15)-6,-326, Nov, 2021
-
日本泌尿器科学会総会プログラム抄録集 (CD-ROM), 102nd ROMBUNNO.APP-184-473, 2014
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集, 23回・43回 244-244, Oct, 2013
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 121 64P-64P, 2013
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 121 181P-181P, 2013
-
J. Res. Inst. Meijo Univ., 12(12) 35-41, 2013 Peer-reviewed
-
日本薬理学会近畿部会プログラム・要旨集 (Kinki Branch Meeting. Japanese Pharmacological Society), 121st(4) 43-4P, 2012
-
Annual Meeting of the Japanese Society of Toxicology, 35(Supplement) S190-308, May, 2010
-
Cancer Research, 70(8_Supplement) 3646-3646, Apr 15, 2010 Peer-reviewedLead authorAbstract Platinum(IV) [Pt(IV)] compounds are being developed worldwide as next-generation platinated drugs for a broad range of cancers. Since Pt(IV) compounds show relatively stable structural features, they are applicable for oral administration. The anti-cancer mechanism of Pt(IV) compounds has been proposed as that Pt(II) generated from Pt(IV) by endogenous reductants binds to DNA, resulting in the inhibition of transcription and replication of cancer cells. Here, we investigated the interaction manner between DNA, Pt(IV) and endogenous reductants such as ascorbic acid (AsA) and glutathione (GSH). cis-Diammine-tetrachloro-Pt(IV) [cis-Pt(IV)], which is a prodrug of cisplatin [cis-diammine-dichloro-platinum(II), cis-Pt(II)], was incubated with calf thymus DNA in the presence of AsA or GSH. In the presence of AsA, cis-Pt(IV) induced oxidative damage in calf thymus DNA, in which elevated amount of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), a biomarker for DNA oxidation, was observed. Hydroxyl radical (HO·) scavengers (ethanol and dimethylsulfoxide) suppressed the AsA-associated oxidative damage in a dose-dependent manner, whereas superoxide dismutase and catalase did not, suggesting that HO· was involved in the DNA oxidation. CD spectral change and crosslink formation in calf thymus DNA were also observed during this DNA oxidation, suggesting the cis-Pt(IV) reduction by AsA and the DNA conformational change by cis-Pt(II)-DNA binding. However, GSH did not show any 8-oxodG formation in calf thymus DNA likely due to its own HO· scavenging capability. GSH also suppressed the cis-Pt(II)-like conformational change probably by cis-Pt(II) sequestering from DNA by GSH. This GSH-cis-Pt(II) complex formation was also suggested by agarose gel electrophoresis. In order to reveal the detailed mechanisms of the complex formation, three thiol compounds (2-mercaptoethanol, 2-mercaptoacetic acid, and 2-mercaptoethylamine) were compared with regard to the reductive complex formation capabilities with cis-Pt(II). As observed in GSH-cis-Pt(IV)-DNA system, 2-mercaptoacetic acid and 2-mercaptoethylamine inhibited cis-Pt(II)-induced CD spectral change and crosslink formation in calf thymus DNA, whereas 2-mercaptoethanol did not, suggesting that thiol- and amine-/carbonyl-groups are involved in GSH-cis-Pt(II) complex formation via ligand exchange between these groups and Cl of cis-Pt(II). In this study, we revealed that the interaction manner of cis-Pt(IV) with endogenous reductants. In the reactions, AsA reduced Pt(IV) to Pt(II) and induced DNA-crosslink formation and DNA oxidation, where HO· was produced; GSH scavenged the radical and interfered with the DNA-crosslink formation. These data strongly indicate the importance of the proper Pt(IV) ligands which are suitable for Pt(IV) reduction by endogenous reductants without complex formation with the generated Pt(II). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3646.
-
Annual Meeting of the Japanese Society of Toxicology, 34(Supplement) S86-3015, Jun, 2009
Books and Other Publications
1Presentations
73Teaching Experience
5-
Apr, 2024 - Present臨床研究コーディネート実習 (Fujita Health University)
-
Apr, 2024 - Present実務実習事前講義・演習 (Meijo University)
-
Apr, 2023 - PresentTraining, Pharmacotherapeutics and informatics (Fujita Health University)
-
May, 2024 - Jul, 2024M1細胞から個体へ (Fujita Health University)
-
Apr, 2023 - Mar, 2024M3医学研究演習 (Fujita Health University)
Professional Memberships
9-
Jun, 2025 - Present
-
Apr, 2025 - Present
-
Oct, 2024 - Present
-
Aug, 2024 - Present
-
Nov, 2023 - Present
Research Projects
10-
日本学術振興会 科学研究費助成事業, Apr, 2026 - Mar, 2029
-
Apr, 2025 - Mar, 2027
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2026
-
研究助成, 公益財団法人 日東学術振興財団, Dec, 2023 - Dec, 2025
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025